Nektar Therapeutics
Delayed Nasdaq - 07/20 10:00:00 pm
48.73USD
-0.71%
Prev.49.0800
Open48.9700
High49.2100
Low47.9900
Volume1 784 498
Financials
Sales 2018 1 183 M
EBIT 2018 695 M
R. net 2018 673 M
Debt 2018 -
Rend. 2018 -
P/E ratio 2018 15,67
P/E ratio 2019
Capi. / Sales 2018 8,49x
Capi. / Sales 2019 36,7x
Capitalization 10 048 M
Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.It operates through the United States and Europe geogrpahical segments.The company was founded in 1990 and is...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
No events available
Trading Rating :
Investor Rating :
Latest news
07/12NEKTAR THERAPEUTICS : Patent Issued for Method of Preparing Carboxylic Acid Functionalized Polymers (USPTO 10011682)
AQ
07/12NEKTAR THERAPEUTICS : Patent Issued for IL-2R.Beta.-Selective Agonists in Combination with an anti-CTLA-4 Antibody Or an anti-PD-1 Antibody (USPTO 10010587)
AQ
07/06S&P 500 ANALYST MOVES : Nktr
AQ
07/05NEKTAR THERAPEUTICS : U.S. Patents Awarded to Inventors in Alabama (July 5)
AQ
07/03S&P 500 MOVERS : Aal, mro
AQ
06/27NEKTAR THERAPEUTICS : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
06/27Free Technical Research on Nektar Therapeutics and Three More Biotech Equities
AC
06/25TODAY'S RESEARCH REPORTS ON TRENDING TICKERS : Novavax and Nektar Therapeutics
AC